Table 1.
The included studies and patients characteristics
| Study | Boyle and Mahawar [15] | Omar et al. [16] | Pizza et al. [17] | Jedamzic et al. [19] | Slagter et al. [9] | Sam et al. [18] | Samuel et al. [14] | Bertrand et al. [20] |
|---|---|---|---|---|---|---|---|---|
| Year | 2020 | 2021 | 2020 | 2020 | 2021 | 2022 | 2019 | |
| Type of study | Retrospective analysis of the prospective hospital database | |||||||
| Follow-up (months) | 24 | 24 | 24 | 24 | 24 | 36 | 12 | 32.4–44.87 |
| 150-cm group (n) | 118 | 171 | 60 | 11 | 172 | 171 | 178 | 392 |
| 200-cm group (n) | 225 | 234 | 60 | 93 | 72 | 234 | 310 | 392 |
| Both groups (n) | 343 | 405 | 180 | 155 | 244 | 405 | 488 | 784 |
| Females: n (%) | 232 (67.6) | 275 (67.9) | 117 (65%) | 111 (71.6) | 199 (81.6) | 275 (67.9) | 327 (67) | 598 (76.3) |
| Mean age | 46.3±12.8 | 46 ± 10.98 | 35.2 ± 9 | 45 ± 4.5 | 48 ± 11 | 46 ± 10.98 | 46.5±7.25 | 44±11.3 |
| Baseline weight | 137.6 | 139±29.96 | 119.9±28.9 | 128.5 (92–196) | 124±17 | 139±29.96 | NA | 121±16, 120±16.6 |
| Baseline BMI | 48.39 | 49±8.14 | 44.93±7.56 | 45.1 (33.1–71.1) | 44±4 | 49±8.14 | 44±2.75 | 43±3.6, 42.6±3.6 |
| 200-cm group EWL% | 75± 20.1 | NA | 61.2 ± 12.1 | 82.2 ± 24.8 | 75 (59–81) | 76.46±20.1 | 68 (53–83) | 76.8 ± 21.6 |
| 150-EWL% mean | 74± 22 | NA | 60.7 ± 16.1 | 63.2 ±17.0 | 83 (65–99) | 75.02+21.35 | 67 (53–80) | 75.5 ± 24.02 |
| 200-TWL% mean | 36.1 ± 9.2 | NA | 41.8 ± 8.9 | 34.5 ± 9.4 | 34 (28–38) | 36.15±9.19 | NA | NA |
| 150-TWL% mean | 34 ± 9.8 | NA | 40.7 ± 9.4 | 33.1 ± 5.2 | 29 (23–36) | 34.12+9.49 | NA | NA |
| Diabetes mellitus resolution: n (%) | ||||||||
| 200-cm group | 29 (46) | NA | 5 (50) | NA | 13 (87) | NA | NA | 45 (48.4) |
| 150-cm group | 12 (46.2) | NA | 5 (45.5) | NA | 21 (68) | NA | NA | 38 (50.7) |
| Diabetes mellitus improvement: n (%) | ||||||||
| 200-cm group | 24 (38) | NA | 3 (30) | NA | 2 (13) | NA | NA | NA |
| 150-cm group | 13 (50) | NA | 2 (18.2) | NA | 10 (32) | NA | NA | NA |
| Hypertension resolution: n (%) | ||||||||
| 200-cm group | 28 (33.7) | NA | 17 (53.1) | NA | 10 (48) | NA | NA | 33 (21.9) |
| 150-cm group | 21 (42.9) | NA | 18 (52.9) | NA | 28 (49) | NA | NA | 31 (22.3) |
| Hypertension improvement: n (%) | ||||||||
| 200-cm group | 24 (28.9) | NA | NA | NA | 11 (52) | NA | NA | NA |
| 150-cm group | 11 (22.4) | NA | NA | NA | 25 (42) | NA | NA | NA |
| Reoperation: n (%) | ||||||||
| 200-cm group | 2 (0.89) | NA | 1 (1.67) | NA | NA | NA | NA | 31 (7.9) |
| 150-cm group | 0 (0) | NA | 2 (3.33) | NA | NA | NA | NA | 16 (4.1) |